-
1
-
-
84924271853
-
Global cancer statistics, 2012
-
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
-
(2015)
CA Cancer J Clin
, vol.65
, pp. 87-108
-
-
Torre, L.A.1
Bray, F.2
Siegel, R.L.3
Ferlay, J.4
Lortet-Tieulent, J.5
Jemal, A.6
-
2
-
-
33644868287
-
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
-
Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-73.
-
(2006)
Carcinogenesis
, vol.27
, pp. 361-373
-
-
Knowles, M.A.1
-
3
-
-
25444467767
-
Urothelial tumorigenesis: A tale of divergent pathways
-
Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 713-725
-
-
Wu, X.R.1
-
4
-
-
0035254218
-
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1, 054 patients
-
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 2001;19:666-75.
-
(2001)
J Clin Oncol
, vol.19
, pp. 666-675
-
-
Stein, J.P.1
Lieskovsky, G.2
Cote, R.3
Groshen, S.4
Feng, A.C.5
Boyd, S.6
-
5
-
-
0033857218
-
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
-
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3068-3077
-
-
von der Maase, H.1
Hansen, S.W.2
Roberts, J.T.3
Dogliotti, L.4
Oliver, T.5
Moore, M.J.6
-
6
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
-
7
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer, C.E.5
Davidson, N.E.6
-
8
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
-
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.J.1
Van Cutsem, E.2
Feyereislova, A.3
Chung, H.C.4
Shen, L.5
Sawaki, A.6
-
9
-
-
77951471947
-
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients
-
Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010;21:815-9.
-
(2010)
Ann Oncol
, vol.21
, pp. 815-819
-
-
Laé, M.1
Couturier, J.2
Oudard, S.3
Radvanyi, F.4
Beuzeboc, P.5
Vieillefond, A.6
-
10
-
-
78649335094
-
Role of anti-Her-2 therapy in bladder carcinoma
-
Marín AP, Arranz EE, Sánchez AR, Auñón PZ, Barón MG. Role of anti-Her-2 therapy in bladder carcinoma. J Cancer Res Clin Oncol 2010;136:1915-20.
-
(2010)
J Cancer Res Clin Oncol
, vol.136
, pp. 1915-1920
-
-
Marín, A.P.1
Arranz, E.E.2
Sánchez, A.R.3
Auñón, P.Z.4
Barón, M.G.5
-
11
-
-
0029655413
-
CerbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value
-
Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. CerbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155:321-6.
-
(1996)
J Urol
, vol.155
, pp. 321-326
-
-
Mellon, J.K.1
Lunec, J.2
Wright, C.3
Horne, C.H.4
Kelly, P.5
Neal, D.E.6
-
12
-
-
0028883362
-
Prognostic value of amplification of c-erb-B2 in bladder carcinoma
-
Lönn U, Lönn S, Friberg S, Nilsson B, Silfverswärd C, Stenkvist B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995;1:1189-94.
-
(1995)
Clin Cancer Res
, vol.1
, pp. 1189-1194
-
-
Lönn, U.1
Lönn, S.2
Friberg, S.3
Nilsson, B.4
Silfverswärd, C.5
Stenkvist, B.6
-
13
-
-
0032519575
-
Invasion of the bladder by transitional cell carcinoma: Its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2
-
Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998;82:715-23.
-
(1998)
Cancer
, vol.82
, pp. 715-723
-
-
Vollmer, R.T.1
Humphrey, P.A.2
Swanson, P.E.3
Wick, M.R.4
Hudson, M.L.5
-
14
-
-
52649176386
-
Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy
-
Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008;40:321-7.
-
(2008)
Int Urol Nephrol
, vol.40
, pp. 321-327
-
-
Kolla, S.B.1
Seth, A.2
Singh, M.K.3
Gupta, N.P.4
Hemal, A.K.5
Dogra, P.N.6
-
15
-
-
14644394929
-
Cell responses to FGFR3 signalling: Growth, differentiation and apoptosis
-
L'Hôte CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005;304:417-31.
-
(2005)
Exp Cell Res
, vol.304
, pp. 417-431
-
-
L'Hôte, C.G.1
Knowles, M.A.2
-
16
-
-
84864917826
-
A decade of FGF receptor research in bladder cancer: Past, present, and future challenges
-
di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012;2012:429213.
-
(2012)
Adv Urol
, vol.2012
-
-
di Martino, E.1
Tomlinson, D.C.2
Knowles, M.A.3
-
17
-
-
0035081241
-
Fibroblast growth factors
-
REVIEWS3005
-
Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2: REVIEWS3005.
-
(2001)
Genome Biol
, vol.2
-
-
Ornitz, D.M.1
Itoh, N.2
-
18
-
-
34548407864
-
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
-
Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91-8.
-
(2007)
J Pathol
, vol.213
, pp. 91-98
-
-
Tomlinson, D.C.1
Baldo, O.2
Harnden, P.3
Knowles, M.A.4
-
19
-
-
78650875209
-
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
-
Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011;104:75-82.
-
(2011)
Br J Cancer
, vol.104
, pp. 75-82
-
-
Lamont, F.R.1
Tomlinson, D.C.2
Cooper, P.A.3
Shnyder, S.D.4
Chester, J.D.5
Knowles, M.A.6
-
20
-
-
66349120144
-
Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer
-
Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009;69:4613-20.
-
(2009)
Cancer Res
, vol.69
, pp. 4613-4620
-
-
Tomlinson, D.C.1
Lamont, F.R.2
Shnyder, S.D.3
Knowles, M.A.4
-
21
-
-
64249099411
-
-
New York: Springer
-
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
-
(2010)
AJCC cancer staging manual. 7th ed
-
-
Edge, S.1
Byrd, D.R.2
Compton, C.C.3
Fritz, A.G.4
Greene, F.L.5
Trotti, A.6
-
22
-
-
84874888512
-
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer
-
Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013;31:731-7.
-
(2013)
J Clin Oncol
, vol.31
, pp. 731-737
-
-
Kim, H.R.1
Kim, D.J.2
Kang, D.R.3
Lee, J.G.4
Lim, S.M.5
Lee, C.Y.6
-
23
-
-
84866516574
-
Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma
-
Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 2012;43:1559-66.
-
(2012)
Hum Pathol
, vol.43
, pp. 1559-1566
-
-
Jung, E.J.1
Jung, E.J.2
Min, S.Y.3
Kim, M.A.4
Kim, W.H.5
-
24
-
-
84864509652
-
FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
-
Jang M, Kim E, Choi Y, Lee H, Kim Y, Kim J, et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res 2012;14:R115.
-
(2012)
Breast Cancer Res
, vol.14
-
-
Jang, M.1
Kim, E.2
Choi, Y.3
Lee, H.4
Kim, Y.5
Kim, J.6
-
25
-
-
78149318726
-
Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer
-
Tomlinson DC, Knowles MA. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol 2010;177:2379-86.
-
(2010)
Am J Pathol
, vol.177
, pp. 2379-2386
-
-
Tomlinson, D.C.1
Knowles, M.A.2
|